RNA
Avidity Biosciences, Inc.
$11.55
-2.12%
$197.6M
No data for this timeframe.
Vol
Market Cap$197.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (80%)
Reddit Sentiment64° Warm
SEC Reports1
Recent Activity
May 24, 2026
clinical_trial_readout
Results Pending: AOC 1020 (Phase 2) — Completed 67d ago
Trial: Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD
May 14, 2026
SEC
Atrium Therapeutics reported Q1 2026 collaboration revenue of $19.6M (vs $2.0M consensus), driven by a $15M milestone fr
8-K — Impact 4/10
Apr 20, 2026
Insider
Younis Husam sold 30,000 shares
Chief Scientific Officer @ $0.00 ($0.00)
Apr 20, 2026
Insider
Younis Husam sold 60,000 shares
Chief Scientific Officer @ $0.00 ($0.00)
Apr 20, 2026
Insider
Hoyos Rocio Martin sold 30,000 shares
Chief Strategy Officer @ $0.00 ($0.00)
Price Targets
$25.00
+112.6% upside
Strong Buy
Current $11.76
Low $25.00
Median $25.00
High $25.00
2 analysts
$25.00
$25.00
Analyst Ratings
1Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | Leerink Partners | INITIATE | Outperform |
| Mar 11, 2026 | Wells Fargo | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.42 ▼ -40.6% | $-1.42 — $-1.42 | 2 | |
| Next Q | $-1.43 ▼ -37.0% | $-1.43 — $-1.42 | 2 | |
| Current FY | $-5.25 ▼ -26.8% | $-5.26 — $-5.24 | 2 | |
| Next FY | $-5.49 ▼ -18.8% | $-6.03 — $-4.95 | -5% YoY | 2 |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 20, 2026 | Younis Husam | A | $0.00 |
| Apr 20, 2026 | Younis Husam | A | $0.00 |
| Apr 20, 2026 | Hoyos Rocio | A | $0.00 |
| Apr 20, 2026 | Hoyos Rocio | A | $0.00 |
| Apr 20, 2026 | Gallagher Kathleen | A | $0.00 |
Reddit Sentiment
64°
Warm
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
11 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 20, 2026 | Younis Husam | Chief Scientific Officer | A | 30,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Younis Husam | Chief Scientific Officer | A | 60,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Hoyos Rocio Martin | Chief Strategy Officer | A | 30,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Hoyos Rocio Martin | Chief Strategy Officer | A | 60,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Gallagher Kathleen P. | See Remarks | A | 102,500 | $0.00 | $0.00 |
| Apr 20, 2026 | Gallagher Kathleen P. | See Remarks | A | 205,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Winslow Brendan R. | Chief Financial Officer | A | 30,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Winslow Brendan R. | Chief Financial Officer | A | 60,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Kenney Stephanie | See Remarks | A | 30,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Kenney Stephanie | See Remarks | A | 60,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Hughes Steven George | Chief Medical Officer | A | 30,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Hughes Steven George | Chief Medical Officer | A | 60,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Boyce Sarah | Director | A | 20,000 | $0.00 | $0.00 |
| Feb 27, 2026 | BOESS CARSTEN | Director | A | 20,000 | $0.00 | $0.00 |
| Feb 27, 2026 | WILSON TROY EDWARD | Director | A | 20,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Flanagan W. Michael | Director | A | 20,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Skerjanec Simona | Director | A | 20,000 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (80% buy). Based on 5 analysts: 1 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$25.00 mean target
+112.6% upside
Strong Buy (3.00)
$25.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $11.76 |
| Target Low | $25.00 |
| Target Mean | $25.00 |
| Target Median | $25.00 |
| Target High | $25.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.42 | $-1.42 | $-1.42 | — | -40.6% | — | $0.0B | — | 2 |
| Next Q 2026-09-30 |
$-1.43 | $-1.43 | $-1.42 | — | -37.0% | — | $0.0B | — | 2 |
| Current FY 2026-12-31 |
$-5.25 | $-5.26 | $-5.24 | — | -26.8% | — | $0.0B | 21.4% | 2 |
| Next FY 2027-12-31 |
$-5.49 | $-6.03 | $-4.95 | -4.6% | -18.8% | — | $0.0B | -82.3% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.420 | |
| 7d ago | $-1.010 | -0.410 |
| 30d ago | $-1.010 | -0.410 |
| 60d ago | $-1.010 | -0.410 |
| 90d ago | $0.000 | -1.420 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | Leerink Partners | INITIATE | — | Outperform |
| Mar 11, 2026 | Wells Fargo | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| May 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Apr 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
64°
Warm
Bearish
Neutral
Bullish
3 mentions
2 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 24, 2026
Clinical Trial
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase Phase 2 — COMPLETED
May 24, 2026
clinical_trial_readout
Results Pending: AOC 1020 (Phase 2) — Completed 67d ago
Trial: Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Sponsor: Avidity Biosciences, Inc.
Phase: Phase
May 11, 2026
Clinical Trial
Global Study of Del-desiran for the Treatment of DM1
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: AOC 1001 (del-desiran) (Phase 3)
Trial: Global Study of Del-desiran for the Treatment of DM1
Sponsor: Avidity Biosciences, Inc.
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING
Conditio
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: AOC 1001 (del-desiran) (Phase 3)
Trial: Global Study of Del-desiran for the Treatment of DM1
Sponsor: Avidity Biosciences, Inc.
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING
Conditio
May 3, 2026
clinical_trial_readout
T-90d Trial Readout: AOC 1001 (del-desiran) (Phase 3)
Trial: Global Study of Del-desiran for the Treatment of DM1
Sponsor: Avidity Biosciences, Inc.
Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING
Conditio
Apr 24, 2026
clinical_trial_readout
Results Pending: AOC 1020 (Phase 2) — Completed 37d ago
Trial: Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Sponsor: Avidity Biosciences, Inc.
Phase: Phase
Mar 6, 2026
short_interest
FTD: RNA — 85,774 shares ($1.3M) failed to deliver
Settlement: 20260306, Price: $15.47, FTD Value: $1,326,923.78, ATRIUM THERAPEUTICS INC COM
Mar 3, 2026
earnings_calendar
RNA Q4 2025 Earnings After Market Close — 2026-03-03
Mar 2, 2026
short_interest
FTD: RNA — 1,154,823 shares ($17.0M) failed to deliver
Settlement: 20260302, Price: $14.75, FTD Value: $17,033,639.25, ATRIUM THERAPEUTICS INC COM
Feb 10, 2026
short_interest
FTD: RNA — 10,023 shares ($0.7M) failed to deliver
Settlement: 20260210, Price: $72.89, FTD Value: $730,576.47, AVIDITY BIOSCIENCES INC COM